Navigation Links
Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
Date:7/30/2008

development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inh
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
2. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
5. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
6. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
8. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
9. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
10. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
11. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 PathoGenetix, Inc. , ... rapid bacterial strain typing, announced today that John ... as Vice President of Engineering. Dr. Luckey will ... RESOLUTION™ Microbial Genotyping System . The fully ... pathogen-specific assay kits, database and software, will be ...
(Date:6/18/2013)... DC (PRWEB) June 18, 2013 On ... Services (CMS) released a final decision memorandum concluding ... to guide subsequent management of anti-tumor strategy, and ... collection. The National Oncological PET Registry (NOPR) was developed ... the first projects under the Coverage with Evidence Development ...
(Date:6/17/2013)... MA (PRWEB) June 17, 2013 ... system in March that helps better monitor potentially harmful ... The microAnalyzer V2.0, which was developed by Draper ... Space Station. , Astronauts breathe air that is processed ... to harmful compounds in the air, even in trace ...
(Date:6/17/2013)... 2013 The Defense Threat Reduction Agency ... at the Waterford in Springfield, Virginia on July 22-25 ... will present technical details on their counter weapons of ... broad range of counter WMD areas including: (1) Science ... Science; (3) Science for Protection; (4) Science to Defeat ...
Breaking Biology Technology:PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 2PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 3WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 2WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 3New Monitoring System Will Better Protect NASA Astronauts on ISS 2Invitation to Register: Annual Defense Threat Reduction Agency Basic Research Technical Review 2
... 2007 -, - Tests Delivered Grew 68 Percent Compared to ... - Conference Call Today at ... Health,Inc. (Nasdaq: GHDX ) today reported financial results and business progress,for ... million in the first quarter of 2008,compared to $14.1 million in the ...
... Pfizer Enterprise 2.0 expert, to deliver keynote address ... ... Pa., May 6 Simon Revell, Manager of Enterprise,2.0 Technology ... Web 2.0,social software can be leveraged to stimulate the advancement ...
... Awards with ,Blue Ladies, a, Masterpiece of a ... CHICAGO, May 6 AbelsonTaylor, long known ... top honors in the medical device category at ... awards ceremony was part of,the DTC National Conference ...
Cached Biology Technology:Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 2Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 3Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 4Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 5Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 6Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 7Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 8Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 9Hershey Center for Applied Research Supports Acceleration of Scientific Research and Development 2Hershey Center for Applied Research Supports Acceleration of Scientific Research and Development 3AbelsonTaylor Captures DTC Gold 2AbelsonTaylor Captures DTC Gold 3
(Date:6/18/2013)... $12.7 million to match nine academic research groups ... explore new treatments for patients in eight disease ... schizophrenia. The collaborative pilot initiative, called Discovering New ... the National Center for Advancing Translational Sciences (NCATS) ... The process of developing a new therapeutic is ...
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
(Date:6/17/2013)... new virus in patients with severe brain infections in ... virus is responsible for the symptoms of disease. , ... out of 644 patients with severe brain infections in ... any of the 122 patients with non-infectious brain disorders ... central nervous system are often fatal and patients who ...
Breaking Biology News(10 mins):NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3
... Charlie Kerfoot,s doughnut, and all fingers point to a European ... No one knew about the doughnut in southern Lake Michigan, ... Charles Kerfoot and his research team first saw it in ... their research vessels on any of the shipwreck-studded Great Lakes ...
... 17, 2010Colon cancer is the second most common cancer in ... year. It has been known for some time that mutations ... of all sporadic colon cancers. Now researchers at Huntsman Cancer ... featured today in Cell the mechanism by which mutation of ...
... We run our modern lives largely by the clock, from ... herald each new workday to the watches and clocks that ... the like. In addition to those ubiquitous timekeepers, ... biological machinery and which help set our circadian rhythms, regulating ...
Cached Biology News:Death of the 'doughnut' 2Death of the 'doughnut' 3Mechanism behind demethylation pinpointed in APC gene mutants 2Tick tock: Rods help set internal clocks, biologist says 2
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Biology Products: